After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
These stocks have both short-term gain catalysts and longer-term growth potential.
DaVita's (DVA) stock rating was reduced to 'neutral' from 'buy' at BofA/Merrill on Tuesday.
Here are Tuesday's top research calls, including an upgrade for Gilead Sciences, downgrades for Biogen and VF Corp., and new coverage for CBS.
Bad news weighs on health care company's stock, which offers an opportunity.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.